Top

Published in:

Open Access 01-12-2009 | Case Report

Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report

Authors: Robert J Brogan, Despina Eleftheriou, James Gnanapragasam, Nigel J Klein, Paul A Brogan

Published in: Pediatric Rheumatology | Issue 1/2009

Abstract

This case report describes an 8 year old boy with IVIG resistant Kawasaki disease complicated by severe bilateral coronary artery aneurysms successfully treated with infliximab, a monoclonal antibody against tumour necrosis factor alpha.

Available only for authorised users

Brogan PA, Bose A, Burgner D, Shingadia D, Tulloh R, Michie C, Klein N, Booy R, Levin M, Dillon MJ: Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child. 2002, 86: 286-90. 10.1136/adc.86.4.286.PubMedCentralCrossRefPubMed

Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA, Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association: Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004, 114: 1708-33. 10.1542/peds.2004-2182.CrossRefPubMed

Gandhi A, Wilson DG: Incomplete Kawasaki disease: not to be forgotten. Arch Dis Child. 2006, 91: 276-7. 10.1136/adc.2005.086884.PubMedCentralCrossRefPubMed

Brogan PA, Shah V, Clarke LA, Dillon MJ, Klein N: T cell activation profiles in Kawasaki syndrome. Clin Exp Immunol. 2008, 151: 267-74.PubMedCentralCrossRefPubMed

Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, Nakamura Y, Yanagawa H, Wakui K, Fukushima Y, Kishi F, Hamamoto K, Terai M, Sato Y, Ouchi K, Saji T, Nariai A, Kaburagi Y, Yoshikawa T, Suzuki K, Tanaka T, Nagai T, Cho H, Fujino A, Sekine A, Nakamichi R, Tsunoda T, Kawasaki T, Nakamura Y, Hata A: ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008, 40: 35-42. 10.1038/ng.2007.59.PubMedCentralCrossRefPubMed

Brogan PA: What's new in the aetiopathogenesis of vasculitis?. Pediatr Nephrol. 2007, 22: 1083-94. 10.1007/s00467-007-0450-1.CrossRefPubMed

Durongpisitkul K, Gururaj VJ, Park JM, Martin CF: The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995, 96: 1057-61.PubMed

Fong NC, Hui YW, Li CK, Chiu MC: Evaluation of the efficacy of treatment of Kawasaki disease before day 5 of illness. Pediatr Cardiol. 2004, 25: 31-4. 10.1007/s00246-003-0558-4.CrossRefPubMed

Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y: Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child. 2008, 93: 142-6. 10.1136/adc.2007.126144.CrossRefPubMed

10.

Dale RC, Saleem MA, Daw S, Dillon MJ: Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr. 2000, 137: 723-6. 10.1067/mpd.2000.108444.CrossRefPubMed

11.

Inoue Y, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, Takeuchi K, Morikawa A: A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr. 2006, 149: 336-41. 10.1016/j.jpeds.2006.05.025.CrossRefPubMed

12.

Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, Atz AM, Li JS, Takahashi M, Baker AL, Colan SD, Mitchell PD, Klein GL, Sundel RP, Pediatric Heart Network Investigators: Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007, 356: 663-75. 10.1056/NEJMoa061235.CrossRefPubMed

13.

Lau AC, Duong TT, Ito S, Yeung RS: Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease. Arthritis Rheum. 2008, 58: 854-63. 10.1002/art.23225.CrossRefPubMed

14.

Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS: Infliximab as a novel therapy for refractory Kawasaki disease. J of Rheumatol. 2004, 31: 808-810.

15.

Oishi T, Fujieda M, Shiraishi T, Ono M, Inoue K, Takahashi A, Ogura H, Wakiguchi H: Infliximab treatment for refractory kawasaki disease with coronary artery aneurysm. Circ J. 2008, 72: 850-2. 10.1253/circj.72.850.CrossRefPubMed

16.

Girish M, Subramaniam G: Infliximab treatment in refractory Kawasaki syndrome. Indian J Pediatr. 2008, 75: 521-2. 10.1007/s12098-008-0084-8.CrossRefPubMed

17.

Stenbog EV, Windelborg B, Horlyck A, Herlin T: The effect of TNFalpha blockade in complicated, refractory Kawasaki disease. Scand J Rheumatol. 2006, 35: 318-21. 10.1080/03009740600588228.CrossRefPubMed

18.

Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, Balfour I, Shen CA, Michel ED, Shulman ST, Melish ME: Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005, 146: 662-7. 10.1016/j.jpeds.2004.12.022.CrossRefPubMed

19.

Stenbog EV, Windelborg B, Horlyck A, Herlin T: The effect of TNF blockade in complicated, refractory Kawasaki disease. Scandinavian Journal of Rheumatology. 2006, 35: 318-321. 10.1080/03009740600588228.CrossRefPubMed

20.

O'Connor MJ, Saulsbury FT: Incomplete and atypical Kawasaki disease in a young infant: Severe, recalcitrant disease responsive to infliximab. Clin Pediatr. 2007, 46: 345-348. 10.1177/0009922806294842.CrossRef

21.

Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GF, Ramilo O: Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008, 153: 833-838. 10.1016/j.jpeds.2008.06.011.PubMedCentralCrossRefPubMed

22.

Clinical Guidelines for immunoglobulin use from Department of Health. [http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_085235]

Title: Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report
Authors: Robert J Brogan
Despina Eleftheriou
James Gnanapragasam
Nigel J Klein
Paul A Brogan
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: Pediatric Rheumatology / Issue 1/2009
Electronic ISSN: 1546-0096
DOI: https://doi.org/10.1186/1546-0096-7-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Nummular keratopathy in a patient with Hyper-IgD Syndrome

Review for the generalist: evaluation of pediatric hip pain

Osteochondritis dissecans and Osgood Schlatter disease in a family with Stickler syndrome

Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis

The differential diagnosis of children with joint hypermobility: a review of the literature

Intra-articular vs. systemic administration of etanercept in antigen-induced arthritis in the temporomandibular point. Part I: histological effects